Publication
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerBreast Carcinomacivic_curation1.00
- cancerLung Carcinomacivic_curation1.00
- cancerMalignant Biliary Tract Neoplasmcivic_curation1.00
- cancerMalignant Uterine Neoplasmcivic_curation1.00
- cancerSolid Neoplasmcivic_curation1.00
- drugOlaparibcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantBRCA1 Mutationcivic_curation1.00
- variantBRCA2 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 41100773
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Mutation + BRCA2 MutationBRCA2BRCA15 | ||||||||
| Olaparib | Breast Carcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12763In the breast carcinoma cohort of the phase II TAPUR trial (NCT02693535), patients with BRCA1/2 alterations treated with olaparib (26 evaluable) had 1 CR (BRCA2 loss), 11 PR (BRCA1 n=5, BRCA2 n=4, BRC… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC | civic |
| 〃 | Lung Carcinoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID12765In the lung carcinoma cohort of the phase II TAPUR trial (NCT02693535), CRs were observed in 2/25 evaluable patients, both with BRCA2 alterations, with DOR of 33 weeks (SCLC, n=1) and 148 weeks (NSCLC… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC | civic |
| 〃 | Malignant Biliary Tract NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12764In the biliary tract carcinoma cohort of the phase II TAPUR trial (NCT02693535), patients with BRCA1/2 alterations treated with olaparib (18 evaluable) had 2 PR (BRCA1 loss n = 1, BRCA2 mutation n = 1… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC | civic |
| 〃 | Malignant Uterine NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID12766In the uterine carcinoma cohort of the phase II TAPUR trial (NCT02693535), PRs were observed in 3 of 15 evaluable patients with BRCA1 (n = 2) or BRCA2 (n = 1) alterations, with response durations of 8… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC | civic |
| 〃 | Solid NeoplasmCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID12767Across all TAPUR cohorts combined (n = 116 evaluable; BC n = 26, BTC n = 18, LC n = 25, UC n = 15, and additional solid tumors with low accural n = 32), patients with advanced solid tumors harboring B… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC | civic |